Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methylphenidate CD
- Development stage
- Approved
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Methylphenidate CD is an extended-release, central nervous system stimulant formulation of methylphenidate hydrochloride. It is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients aged 6 to 15 years and adults. The formulation contains both immediate-release (IR) and extended-release (ER) beads, with approximately 30% of the dose released immediately and 70% released gradually over several hours, providing a biphasic plasma concentration profile. Methylphenidate acts primarily by blocking the reuptake of norepinephrine and dopamine into presynaptic neurons and increasing their release into the extraneuronal space, thereby enhancing neurotransmitter activity in the brain[1][3][5]. The d-threo enantiomer is more pharmacologically active than the l-threo enantiomer[1][5]. Methylphenidate CD may help increase attention span while reducing impulsiveness and hyperactivity in patients with ADHD[1][2].
- Brand names
- Metadate CD
- Other names
- methylphenidate hydrochloride extended-release capsules CDmethylphenidate HCl extended-release capsules CD
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2B (5-Hydroxytryptamine Receptor 2B)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on methylphenidate CD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methylphenidate CD.